Kidney Disease & Nephrology Clinical Trials Update: Week 27, 2026

Published July 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

This Phase 4 trial by Unity Health Toronto is studying semaglutide, a once-weekly injection, in people with diabetes who are on maintenance dialysis. The goal is to check if semaglutide is safe and well tolerated in this group. If it works well, it might offer an easier treatment option that could also help protect the heart, which is important since cardiovascular problems are common in dialysis patients. The study is recruiting in Canada and will follow participants for 26 weeks.

Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

Western University in Canada is testing a weight management program that combines semaglutide with virtual coaching for people with obesity and chronic kidney disease who are waiting for a kidney transplant. Losing weight safely could improve their chances of getting a transplant and better outcomes after surgery. This Phase 4 trial plans to enroll 60 participants and is currently recruiting in Canada.

Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes

The University of Colorado is running a Phase 4 study to see if montelukast, a medication that blocks inflammation, can help people with type 1 diabetes and kidney disease marked by protein in the urine (albuminuria). The researchers want to find out if montelukast can reduce kidney damage and improve heart and blood vessel health. This study is recruiting 50 participants in the United States.

Renal Anhydramnios Fetal Therapy

Johns Hopkins University completed a Phase 1 trial testing serial amnioinfusions for fetuses with renal anhydramnios, a rare condition causing very low amniotic fluid and underdeveloped lungs. This treatment aims to improve lung growth and increase survival chances for affected babies, who often face fatal outcomes without intervention. The study was conducted at multiple US centers and results are now available.

A Culturally Targeted Transplant Program

Northwestern University is evaluating a transplant program designed specifically for Hispanic adults with end-stage renal disease. This program aims to increase living donor kidney transplants for Hispanic patients, who often experience longer wait times and lower survival rates. By addressing cultural factors, this effort hopes to reduce disparities and improve transplant access and outcomes. The study is ongoing at multiple centers in the United States.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.